Enid

Researchers are evaluating a one-year version of the Parent-Child Assistance Program PCAP-1, a home visitation and case management program designed to support parents who have used substances during pregnancy or postpartum. The study aims to assess PCAP-1s effectiveness in preventing foster care placement, promoting family reunification, supporting parent recovery, and connecting parents to community resources. This evaluation addresses a knowledge gap by focusing on a vulnerable population with high child welfare involvement and substance use challenges. Participants in the treatment group will receive PCAP-1 services for one year, involving biweekly meetings with trained case managers either in the home or community settings. Case managers help parents set personal goals, provide support, and connect them with tailored resources. The control group will include parents matched from administrative data who receive usual community services but not PCAP. The program adaptation to one year aligns with federal funding timelines and may better fit families involved in child welfare. During the study, participants will complete self-administered surveys at baseline, 12 months, and 18 months to capture behaviors and social factors related to addiction and family well-being. Case managers will submit regular reports on client progress, including substance use, child custody, and service connections. Administrative child welfare data will provide detailed information on foster care placements and reunifications. The study will measure outcomes such as the proportion of children not placed in foster care and parents maintaining custody after one year, along with secondary outcomes related to housing, employment, education, public benefits, and criminal justice involvement. Participation spans up to 18 months with ongoing monitoring.

Researchers are comparing the rates of surgical and minimally invasive interventions, as well as any harms, in Medicare beneficiaries treated with the MILD procedure versus those treated with interspinous process decompression IPD for lumbar spinal stenosis with neurogenic claudication. This observational study uses Medicare claims data to follow patients for 24 months after their initial procedure starting from January 1, 2017. The purpose is to evaluate outcomes between these two types of procedures without requiring prior patient enrollment or consent. The study includes two groups patients who received MILD, which is a percutaneous image-guided lumbar decompression performed under fluoroscopic guidance through a dorsal approach to the spine, and patients who received IPD, a different device-based decompression procedure. Data on reoperations and complications will be collected for both groups over a 24-month follow-up period using Medicare claims. Enrollment continues until the sponsor decides to stop. Participants involvement is passive as the study uses existing Medicare claims data. Researchers will monitor rates of harms related to the initial procedure and subsequent surgical or minimally invasive interventions over two years. No direct patient visits or interventions are conducted, and the study is exempt from institutional review board oversight. The total study duration extends to December 2026, covering cases treated since early 2017.

This trial investigates the safety and effectiveness of two head lice treatments Elimax Green Lotion Emogreen and Walgreens Lice Killing Shampoo. It includes individuals aged 6 months and older who have confirmed head lice infestations. The research focuses on comparing how well these products work and their safety, including monitoring for skin and eye irritation and any adverse events during the study. Participants are randomly assigned to one of two groups one group receives the Elimax Green Lotion with Emogreen, a device-based treatment that physically suffocates lice using bio-alkane and beeswax, combined with a lice comb the other group receives Walgreens Lice Killing Shampoo containing Piperonyl Butoxide and Pyrethrum Extract. The treatments are applied to dry hair, left on for 10 minutes, then washed out, followed by combing to remove lice and nits. Participants may need to repeat treatment if lice persist, with follow-up over 7 to 10 days. Throughout the study, participants undergo regular assessments including evaluation of lice cure rate by day 10, tolerability checks for skin and eye irritation, and monitoring for any adverse events. Additional evaluations include esthetic properties of the hair on days 0 and 7. Participants are expected to follow study instructions strictly and attend scheduled visits, with overall participation lasting through the 10-day treatment and observation period.